Discovery of a novel class of broad-spectrum antivirals targeting the UEV domain of TSG101 in the host ESCRT pathway

  • Eur J Med Chem. 2026 Nov 15:318:119162. doi: 10.1016/j.ejmech.2026.119162.
Daniele Rubini  1 ,  Marisa Parra-López  2 ,  Julia Holzerland  3 ,  Alejandro Rodríguez-Martínez  4 ,  Maria Grazia Martina  1 ,  Martina Eleonora Valenti  1 ,  Maria C Ramos  5 ,  Francisco Castillo  5 ,  Ronald N Harty  6 ,  Kristina Lanko  7 ,  Lisa Bauer  8 ,  Horacio Pérez-Sanchez  9 ,  Sandra Diederich  3 ,  Irene Luque  10 ,  Marco Radi  11
Affiliations
  • 1. Dipartimento di Scienze degli Alimenti e del Farmaco (DipALIFAR), Università degli Studi di Parma, Viale delle Scienze, 27/A, Parma, 43124, Italy.
  • 2. Department of Physical Chemistry, Institute of Biotechnology, and Unit of Excellence in Chemistry Applied to Biomedicine and Environment, School of Sciences, University of Granada, Granada, 18071, Spain.
  • 3. Institute of Novel and Emerging Infectious Diseases, Friedrich-Loeffler-Institut, Federal Research Institute of Animal Health, Insel Riems, Greifswald, 17493, Germany.
  • 4. Structural Bioinformatics and High-Performance Computing Research Group (BIO-HPC), UCAM Universidad Católica de Murcia (UCAM), HiTech Innovation Hub, Murcia, 30107, Spain; Health Sciences PhD Program, Universidad Católica de Murcia UCAM, Campus de los Jerónimos n°135, Murcia, Guadalupe, 30107, Spain.
  • 5. Fundación MEDINA, Parque Tecnológico de la Salud, Av. Conocimiento 34, Granada, 18016, Spain.
  • 6. Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • 7. Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, the Netherlands.
  • 8. Department of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands.
  • 9. Structural Bioinformatics and High-Performance Computing Research Group (BIO-HPC), UCAM Universidad Católica de Murcia (UCAM), HiTech Innovation Hub, Murcia, 30107, Spain.
  • 10. Department of Physical Chemistry, Institute of Biotechnology, and Unit of Excellence in Chemistry Applied to Biomedicine and Environment, School of Sciences, University of Granada, Granada, 18071, Spain. Electronic address: [email protected].
  • 11. Dipartimento di Scienze degli Alimenti e del Farmaco (DipALIFAR), Università degli Studi di Parma, Viale delle Scienze, 27/A, Parma, 43124, Italy. Electronic address: [email protected].
Abstract

The persistent threat of emerging and re-emerging viral outbreaks underscores an urgent need for broad-spectrum antivirals (BSAs). A promising strategy involves targeting host factors exploited by different viral families to develop new BSAs with a high barrier to resistance development. The present work focuses on the inhibition of the protein-protein interactions (PPIs) between viral late domains (L-domain) and the TSG101 protein from the host ESCRT pathway, which is exploited by multiple highly pathogenic viruses for their replication and budding, hence representing a crucial yet underexplored therapeutic strategy to inhibit viral replication. Starting from the previously identified hit compound UEV-10, we developed a series of simplified, more druggable quinoline analogues. These derivatives effectively inhibited the TSG101/L-domain interaction at low micromolar concentrations and were active in a series of cell-based assays, including high-content bimolecular complementation, virus-like particle release, and viral growth inhibition of several biosafety level 4 (BSL-4) pathogens (Ebola, Marburg, and Nipah viruses) and non-enveloped enteroviruses (EV-D68). Overall, our findings further support the inhibition of TSG101/L-domain PPIs as an effective and versatile strategy for the development of broad-spectrum Antiviral agents with potential applicability across diverse viral families.

Products